CLEER-001
Phase 2A Clinical Trial
Primary Inclusion Criteria
- Patients 18 years and older
- Prescribed FDA Approved EGFR Inhibitor Therapy
- Developed Acneiform Rash Grade 3 or lower
Preliminary Results
Current Sites & Contact
Please contact Sponsor, Hoth Therapeutics, directly at: admin@hoththerapeutics.com
Check here for all clinical sites currently enrolling to discuss enrolment with a site/PI near you.